Novartis honored by Malaria No More corporate citizenship award in recognition of long-standing commitment to eliminating the disease
Since 2001, Novartis has delivered more than 600 million antimalarial treatments without profit
For over a decade, the company has adopted an innovative approach to the fight against malaria
Novartis remains committed to working with partners to develop new treatments and new ways to reach patients
Basel, November 14, 2013- In recognition of Novartis' significant on-going contributions to malaria control and elimination, the company has been honored with the Global Corporate Citizenship Award at the Malaria No More International Honors annual benefit.
Since 2001 Novartis has delivered more than 600 million antimalarial treatments to malaria-endemic countries across Africa, without profit. The company also adopts an innovative approach in its long-standing efforts to eliminate malaria and has invested in partnerships to maximize the impact of its efforts. In collaboration with Medicines for Malaria Venture, Novartis was first to develop a sweet-tasting dispersible artemisinin-based combination therapy (ACT) treatment specifically for infants and children, which was launched in 2009.
"Novartis is a corporate pioneer in its work to reduce the burden of malaria, partnering on a range of innovative programs that have enabled access to essential medicines for hundreds of millions of people," noted Martin Edlund, CEO of Malaria No More. "Simply put, we could not achieve our mission to end deaths from malaria without the leadership of Novartis, and we hope more companies will follow their example."
In 2010, Novartis rolled out "SMS for Life"; a program which uses mobile technology to manage delivery and stock levels of life-saving antimalarial medicines for rural health facilities. This year, Novartis joined forces with Malaria No More and supports the Power of One campaign to help close the treatment gap in Africa. Malaria is a preventable and treatable disease, but still kills one child every minute, and every dollar donated buys and delivers a treatment to a child diagnosed with the disease.
"We are honored to receive this award and proud of the significant contributions Novartis has made in the past two decades in the fight against this deadly disease," said Joerg Reinhardt, Chairman of the Novartis Board of Directors. "However we still face a significant problem and more is required, with cross-industry partnerships essential to ensuring that we make the difference needed."
The International Honors Awards acknowledge the support of global efforts against malaria and also recognized Hillary Rodham Clinton, Former Secretary of State and Former U.S. Senator from New York, as well as Gary Ginsberg, Executive VP of Corporate Marketing and Communications at Time Warner Inc.
"Through the Malaria Initiative and associated programs, we are committed to improving access to treatment, helping communities deliver better healthcare and investing in research and development into the next generation of antimalarials, contributing to reducing the risk of malaria for millions of people across the world," said Dr. Linus Igwemezie, Head of the Novartis Malaria Initiative.
About the Novartis Malaria Initiative The Novartis Malaria Initiative is one of the largest access-to-medicine programs in the healthcare industry. Moving forward, Novartis is committed to malaria elimination by driving the development of next-generation antimalarials, with two new classes of drugs currently in development. The most advanced compound is in Phase II clinical trials.
About Novartis Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 133,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.